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Abstract 
Rat hepatocytes have previously been reported to possess prostaglandin E, receptors of the EP,-type (EP,-receptors) that inhibit glucagon- 
stimulated glycogenolysis bydecreasing CAMP. Here, the isolation of a functional EP, receptor cDNA clone from a rat hepatocyte cDNA library 
is reported. This clone can be translated into a 362-amino-acid protein, that displays over 95% homology to the EP, receptor from mouse 
mastocytoma. The amino- and carboxy-terminal region of the protein are least conserved. Transiently transfected HEK 293 cells expressed a single 
binding site for PGE, with an apparent Kd of 15 nM. PGE, > PGF,, > PGDz competed for [‘HIPGEl binding sites as did the EP, receptor agonists 
M&B 28767 = sulprostone > misoprostol but not the EP, receptor antagonist SC 19220. In stably transfected CHO cells M&B 28767 > sulprostone 
= PGE, > misoprostol > PGF, inhibited the forskolin-elicited CAMP formation. Thus, the characteristics of the EP, receptor of rat hepatocytes 
closely resemble those of the EP, receptor of mouse mastocytoma. 
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1. Introduction 
Hepatocyte carbohydrate metabolism has been shown 
to be modulated by prostaglandins in two opposing 
ways: In unstimulated rat hepatocytes prostaglandins 
F 2a, E, and Dz increased InsP, formation, glycogen 
phosphorylase activity and glucose output apparently 
via PGF?, receptors (FP receptors) and PGE2 receptors 
of the subtype 1 (EP, receptors) that are linked to phos- 
pholipase C by a G, protein [l-5]. In contrast, in rat 
hepatocytes stimulated with glucagon PGE, and to a 
lesser extent PGF,, and PGD, inhibited the glucagon- 
induced increase in CAMP formation, glycogen 
phosphorylase activity and glucose output. These latter 
effects were mediated via PGE, receptors of the subtype 
3 (EP, receptors) that inhibit adenylate cyclase via a 
pertussis toxin sensitive G, protein [3,&B]. Rat hepato- 
cytes may also contain PGE2 receptors of the subtype 2 
(EP, receptors) which activate adenylate cyclase via a G, 
protein [3,6]. 
In the last three years structural information about 
prostanoid receptors, that had so far been charaterized 
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R. norvegicus mRNA for hepatocyte EP3 beta receptor. 
only pharmacologically, has been gained by molecular 
cloning and expression [9,10]. The sequence data availa- 
ble on the human thromboxane A, receptor [l l] and the 
mouse mastocytoma PGE2 receptor (subtype EP,) [12, 
131 made it possible to characterize the rat hepatic pros- 
taglandin receptors on a molecular level. Here, as a first 
hepatic prostaglandin receptor, the molecular cloning, 
expression and characterization of the rat hepatocyte 
PGE, receptor of the EP, subtype is reported. 
2. Materials and methods 
2.1. Materials 
All materials were of analytical grade and from commercial sources. 
M&B 28767, sulprostone, misoprostol and SC-19920 were generous 
gifts from Rhone-Poulenc Rorer (Dagenham, UK), Schering Pharma- 
ceutical (Berlin, Germany) and Searle (Skokie, USA), respectively. 
[‘H]PGE2 was obtained from Amersham (Braunschweig, Germany), 
unlabeled prostaglandins were purchased from Paesel (Frankfurt, Ger- 
many) or Cascade (Berkshire, UK). Geneticin (G-418 sulphate) was 
obtained from Gibco-BRL (Eggenstein, Germany) and forskolin was 
from ICN (Meckenheim, Germany). The sources of other materials are 
given in the text. 
2.2. Hepatocyte p&cation 
Hepatocytes were isolated from male Wistar rats (200-260 g) accord- 
ing to Meredith [14] without the use of collagenase by perfusion with 
Ca”-free Krebs-Henseleit buffer containing 2 mM EDTA as described 
previously [3]. The bulk of detritus and non-parenchymal cells were 
removed by repeated sedimentation of hepatocytes at 50 x g. Viable 
hepatocytes were further purified by centrifugation through a gradient 
containing 58% Percoll. 
2.3. PCR-amplification of EP, receptor cDNA fragments 
Total RNA was isolated from purified hepatocytes by CsCl gradient 
centrifugation [I 51. Poly(A)’ mRNA was prepared by affinity purifica- 
tion using oligo-(dT) beads from Quiagen (Rathingen, Germany) ac- 
cording to the manufacturer’s instructions. First strand cDNA was 
synthesized by reverse transcription using oligo-(dT),,,, (Pharmacia, 
0014-5793/94/$7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(94)00837-X 
120 
Freiburg, Germany) as a primer. PCR was carried out using l-10 ng 
first strand cDNA as a template and oligonucleotide primers corre- 
sponding to position 651-680 and 12641293 of the mouse EP, se- 
quence [13]. Thirty-five cycles of PCR were performed with the follow- 
ing temperature profile: 40 s 95”C, 40 s 60°C and 1.5 min 72°C. A 640 
bp and a 730 bp fragment were amplified and cloned into PUC18 
(Pharmacia). Nucleotide sequence analysis was carried out on double 
stranded templates using the dideoxy chain termination method [16] 
2.4. EP, receptor cDNA cloning 
Rat hepatocyte cDNA was prepared from hepatocyte poIy(A)+ 
RNA by an oligo-(dT) priming method using a cDNA synthesis kit 
(Pharmacia) and inserted into the J&RI site of agtl 1 (Gibco-BRL) 
DNA with EcoRI adaptors including an internal Not1 site (Pharmacia). 
The lo6 clones derived from this library were screened by hybridisation 
with the cloned 640 and 730 bp EP, receptor probes labelled with 
digoxigenin by PCR replacing 5% of the dTTP by ll-digoxygenin- 
dUTP. Positive plaques were isolated and analysed with restriction 
digestion and PCR. The cDNAs of three clones were amplified by PCR 
using primers flanking the EcoRI cloning site, subcloned into PUC18 
and sequenced. 
2.5. Transient expression of the EP, receptor cDNA in HEK293 cells 
The full-length 2.0-kb Not1 cDNA fragment of one clone (clone 15/l) 
was subcloned into the eucaryotic expression vector pcDNA I (Invitro- 
gen, San Diego, USA). The resultant plasmid was transfected into 
HEK293 cells by a calcium phosphate method using 5% (v/v) modified 
bovine serum from Stratagene (La Jolla, USA). Cells were cultured for 
72 h in DMEM with 10% FCS and then scraped into a homogenization 
buffer containing 25 mM Tris-HCl pH 7.5, 250 mM sucrose, 10 mM 
MgCl,, 1 mM EDTA and 1 mM phenyl-methyl-sulfonyl-fluoride 
(PMSF). After homogenization of the cells in a dounce homogenizer 
a crude membrane fraction was prepared by centrifugation of the ho- 
mogenate at 100,000 x g. The resulting pellet was suspended in binding 
buffer containing 25 mM Tris-HCI pH 6.2, 10 mM MgCI, and 1 mM 
EDTA and stored at -20°C. 
2.6. PGEz binding assays with membranes of transfected HEK293 cells 
For ligand binding membranes (20-50 pg protein) wer? incubated 
with 5 nM [‘HIPGE, and various concentrations of unlabelled prosta- 
glandins, receptor agonists and antagonists in lOOfi1 binding buffer for 
1 h at 20°C. Non-specific binding was determined in presence of 10 PM 
PGEr. Bound and unbound ligand were separated by rapid vacuum 
filtration through GF 52 filters (Schleicher and Schtlll, Dassel, Ger- 
many) [17]. Filters were washed with 4 ml ice-cold binding buffer. 
Radioactivity retained on the filter was counted in 5 ml Hydroluma 
(Baker, Deventer, NL). Binding constants were calculated by non- 
linear regression analysis (LIGAND [18]). 
2.7, Stable expression of EP, receptor cDNA in CHO cells 
The full-length 2.0-kb Not1 cDNA fragment of clone 15/l was sub- 
cloned into the eucaryotic expression vector pRc/CMV (Invitrogen). 20 
pg of the resultant plasmid were linearized and transfected into 10’ 
CHO cells by electroporation. Transfectants were isolated by growing 
the cells in HAM F-12 medium containing 10% (v/v) FCS and 1.2 
mg/ml G-418 as substrate of the selection marker aminoglycoside 
phosphotransferase (NEO). Clonal cell lines were isolated by single cell 
cloning and tested for expression by PGE, binding and inhibition of 
forskolin-induced CAMP formation. 
2.8. CAMP-formation in transfected CHO ceils 
CHO cells expressing the cDNA of clone 15/l were cultured in 3.5 
cm diameter plates to a density of 5 x lo5 in HAM-F12 medium con- 
taining lO%(v/v) FCS. Cells were washed 3 times with 1 ml HEPES 
buffer pH 7.4 containing 140 mM NaCl, 4.7 mM KCI, 2.2 mM CaCl,, 
1.2 mM KH,PO,, 11 mM glucose and 15 mM HEPES and then pre- 
incubated in 1 ml of the same buffer with 1 mM IBMX at 37°C for 10 
min. Then prostaglandins, receptor agonists and forskolin (1 pM) were 
added in a volume of 10 ~1 buffer to the final concentration indicated. 
After incubation for 10 min the reaction was stopped by removing the 
buffer and freezing the cells in liquid nitrogen. Cells were lysed in 500 
~1 10 mM HCl containing 1 mM IBMX for 1 h at 4°C. The lysate was 
centrifuged and CAMP was quantified in the supernatant with a 
[‘*‘I]cAMP assay kit of Amersham. 
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3. Results and discussion 
3.1. Sequence of the rat hepatocyte EP, receptor 
Hepatocyte cDNA was used as template for PCR. The 
primer corresponded to position 65 l-680 and 1264-l 293 
of the published sequence of the mouse mastocytoma 
EP3 receptor [13]. PCR yielded two products of about 
640 and 730 bp (not shown) as described for mouse 
kidney, uterus, stomach and lung [I 31. The PCR prod- 
ucts were cloned into PUC 18 and partially sequenced. 
They showed high homology to the a and p splice vari- 
ants of the mouse mastocytoma EP3 receptor, which 
contain 365 and 361 amino acids, respectively and differ 
only in their C-terminal peptide [ 131. Both PCR products 
were labelled with digoxigenin and used to screen a rat 
hepatocyte cDNA library in lZgt 11. Three cDNA clones 
were isolated. 
Clone 15/l was subcloned into PUC 18 and sequenced 
in both directions. An open reading frame of 1086 bp 
. 
GAGCCGGGCAGCGTGGCCTTTGCCTCCGCCTTCGCCTTCGCCTGTCTAffiCTT~T~CTCT~TG 
EPGSVAFASAFACLGLLAL” 
/r 
GTGACCTTTGCCTGCAACCTGGCGACCATCARAGCCCTGGTGTCCCGCTGCCGGGCCAM 
VTFACNLAT IKALVSRCRAK 
GCCGCCGCCTCGCAGTCCAGCGCCCAGTGGGGCCGGATCG 
AAASQSSAQWGRITTETAIQ 
CTTATGGGGATCATGTGTGTACTGTCCGTCTGCTG(;TC~CGCTATTGAT~TGATGCTG 
LMGIMCVLSVCWS PLLIMML 
"I 
-TGATCTTCAATCAGATGTCAGTACIAGCAATGCAAG 
KM I FNQMSVEQCKTQMGKEK 
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Fig. 1. Nucleotide and deduced amino acid sequence of the rat hepato- 
cyte EP,@ receptor. Amino acids differing from the mouse mastocytoma 
EP, receptor are printed in bold face, putative transmembrane r gions 
are underlined and numbered with roman numerals. Potential phos- 
phorylation sites for protein kinase A and N-glycosylation sites are 
marked by diamonds and hearts, respectively. 
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could be translated into a 362 amino acid protein (Fig. 
1). The protein displayed ~95% sequence homology with 
the mouse mastocytoma EP, receptor [13]. While this 
work was in progress additional prostaglandin receptors 
have been cloned. The rat EP, receptor showed 85% 
homology to the human [19] and 83% to the rabbit 
[20] kidney EP,, receptor. Sequence homologies to 
mouse mastocytoma EP1, EP,, and mouse ovary FP re- 
ceptors [21-231 were below 50%. Non-conservative 
exchanges were clustered in the N- and C-terminal 
domain. 
The sequence-deduced molecular mass was 39628 Da. 
Hydrophobicity analysis indicated the existence of 7 
membrane spanning domains and a hydrophobic C-ter- 
minus similar to the mouse EP, receptor. Protein kinase 
A phosphorylation sites (Ser-59 and Ser-64) and N-gly- 
cosylation sites (Asn-16 and Asn-194) described for the 
mouse mastocytoma EP, receptor and the EP,, receptor 
from rat kidney [24] were preserved. In the middle of the 
cDNA (position 453459) an additional triplet was lo- 
cated. Thereby a proline was replaced by an Arg and Ala 
which are not present in the mouse EP,, and EP, [I 31 
receptor and the EP,, receptor from rat kidney [24], yet 
were found in the EP,, receptor from human [19] and 
rabbit [20] kidney. The C-terminal /I-peptide of the 
mouse mastocytoma EP, receptor contains 3 Ser and 
1 Thr, that are 4 potential phosphorylation sites which 
have been proposed to play a role in the regulation of the 
signalling activity of ligand-occupied receptors [131. No- 
tably, all these potential phosphorylation sites in the 
C-terminal /I peptide are conserved. Yet Thr-343 of the 
mouse mastocytoma /I peptide is replaced by Ser-344 in 
the rat hepatocyte EP, receptor. Futhermore, Gly-352 
of the mouse mastocytoma EP, receptor is replaced by 
a Ser-353 of the rat hepatocyte EP, receptor. Thus, the 
rat EP, receptor C-terminal peptide contains an addi- 
tional potential phosphorylation site. 
3.2. Ligand binding properties of the transiently 
expressed EPJB receptor 
The cDNA of clone 15/l was subcloned into pcDNA 
I and transiently expressed in HEK293 cells. Membranes 
of the cells transfected with pcDNA I 15/l, in contrast 
to membranes of mock transfected cells, expressed a 
unique PGE,! binding site with an apparent & of 15 nM. 
About 0.6 pmol receptor per mg membrane protein were 
expressed. PGF,, and PGD, competed with [‘HIPGE, 
for its binding site with about lOO- and lOOO-fold lower 
affinity, respectively (Fig. 2). The EP, receptor subtype 
agonists M&B 28767 and sulprostone had a slightly 
higher affinity for the PGE, binding site than had PGE, 
(Fig. 2), whereas the EP, receptor agonist misoprostol 
had a roughly lo-fold lower affinity. The EP, receptor 
ligand SC 19920 did not compete with [3H]PGE,. The 
ligand binding properties are similar to those described 
for the EP, receptor of mouse mastocytoma [131 except 
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Fig. 2. Competition by PGE*, PGF,, PGD,, M&B 28767, sulprostone, 
misoprostol and SC 19920 of [‘HIPGE, binding to membranes of 
pcDNA I IS/l transfected HEK293 cells. HEK293 cells were trans- 
fected with the pcDNA I 15/l construct. Binding of 5 nM [3H]PGE, was 
measured after 1 h at 20°C in presence of the concentrations of unla- 
belled prostaglandins and their analogs indicated. MandB 28767, sul- 
prostone and misoprostol are EPr receptor agonists, SC 19920 is an EP, 
receptor antagonist. [rH]PGE, binding in presence of IOyM PGE, was 
defined as unspecific binding. 
that the apparent & for PGE, binding was about 5-fold 
higher. 
3.3. Functional properties of the stably expressed EP, 
receptor 
Clone 15/l was subcloned into pRc/CMV and stably 
expressed in CHO cells. Expression of a PGE, binding 
site was about lo-fold lower than in HEK293 cells tran- 
siently transfected with pcDNA I 15/l (not shown). In 
transfected CHO cells PGE, inhibited the forskolin-in- 
duced CAMP formation up to 60% (Fig. 3). About 10 nM 
PGEz caused a half-maximal inhibition. 50-fold higher 
concentrations of PGF*, were needed for half-maximal 
inhibition. PGD,, despite of its binding to the PGE, 
receptor, did not significantly reduce forskolin-induced 
CAMP formation in CHO cells. The EP, subtype ag- 
onists M&B 28767, sulprostone and misoprostol inhib- 
ited forskolin-induced CAMP formation with decreasing 
potency (Fig. 3). The concentrations of prostaglandins 
and their analogs that inhibited forskolin-stimulated 
CAMP formation half-maximally were in the same con- 
centration range as needed for 50% competition of 
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Fig. 3. Inhibition of forskolin-stimulated CAMP formation in pRc/ 
CMV 15/l transfected CHO cells by PGE,, PGF,,, PGD,, M&B 28767, 
sulprostone and misoprostol. CHO cells were stably transfected with 
the pRc/CMV 15/l construct. CAMP formation induced by 1 PM fors- 
kolin after 10 min at 37°C in presence of the concentrations indicated 
of PGE,, PGF,, PGD, or the EP, receptor agonists M&B 28767, 
sulprostone and misoprostol was determined by radioimmuno assay. 
CAMP formation in absence of prostaglandins was set equal to 100%. 
[3H]PGE, binding. Mock transfected CHO cells did nei- 
ther express a PGE, binding site nor was forskolin-stim- 
ulated CAMP formation inhibited by PGE,. 
The functional properties of the cloned rat hepatocyte 
EP, receptor were very similar to those of the mouse 
mastocytoma EP, receptor [13], yet differed slightly 
from the properties of the Gi coupled PGE, receptor in 
isolated rat hepatocytes 131. In hepatocytes glucagon- 
induced CAMP formation was inhibited by PGE,. For 
half-maximal inhibition of glucagon-induced CAMP for- 
mation in hepatocytes about 30-fold higher concentra- 
tions of PGE, were needed then for half-maximal inhibi- 
tion of forskolin-induced CAMP formation in transfected 
CHO cells. Furthermore, in hepatocytes misoprostol and 
sulprostone had a roughly identical ED,, for the inhibi- 
tion of glucagon-induced CAMP formation, whereas in 
transfected CHO-cells sulprostone was clearly more po- 
tent than misoprostol. This might be due to a different 
equipment with Gi proteins in hepatocytes and CHO 
cells. It might also be due to differences in the metabo- 
lism of prostaglandin E, and its analogs by hepatocytes 
and CHO cells. PGE, is very rapidly inactivated and 
degraded in hepatocyte cultures and suspensions by per- 
oxysomal /Loxidation, o-oxydation and oxidation of the 
C-15 OH group [25]. It is, therefore, not clear at present 
whether the newly cloned EP3B-receptor f om rat hepato- 
cytes is involved in the inhibition of glucagon-induced 
CAMP formation, glycogen phosphorylase activation 
and glucose output from rat hepatocytes. 
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